An updated review of gastric cancer in the next-generation sequencing era: Insights from bench to bedside and vice versa

Hiroyuki Yamamoto, Yoshiyuki Watanabe, Tadateru Maehata, Ryo Morita, Yoshihito Yoshida, Ritsuko Oikawa, Shinya Ishigooka, Shun Ichiro Ozawa, Yasumasa Matsuo, Kosuke Hosoya, Masaki Yamashita, Hiroaki Taniguchi, Katsuhiko Nosho, Hiromu Suzuki, Hiroshi Yasuda, Yasuhisa Shinomura, Fumio Itoh

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Gastric cancer (GC) is one of the most common malignancies and remains the second leading cause of cancer-related death worldwide. There is an increasing understanding of the roles that genetic and epigenetic alterations play in GCs. Recent studies using nextgeneration sequencing (NGS) have revealed a number of potential cancer-driving genes in GC. Whole-exome sequencing of GC has identified recurrent somatic mutations in the chromatin remodeling gene ARID1A and alterations in the cell adhesion gene FAT4, a member of the cadherin gene family. Mutations in chromatin remodeling genes (ARID1A, MLL3 and MLL) have been found in 47% of GCs. Whole-genome sequencing and whole-transcriptome sequencing analyses have also discovered novel alterations in GC. Recent studies of cancer epigenetics have revealed widespread alterations in genes involved in the epigenetic machinery, such as DNA methylation, histone modifications, nucleosome positioning, noncoding RNAs and microRNAs. Recent advances in molecular research on GC have resulted in the introduction of new diagnostic and therapeutic strategies into clinical settings. The antihuman epidermal growth receptor 2 (HER2) antibody trastuzumab has led to an era of personalized therapy in GC. In addition, ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor (VEGFR)-2, is the first biological treatment that showed survival benefits as a single-agent therapy in patients with advanced GC who progressed after firstline chemotherapy. Using NGS to systematically identify gene alterations in GC is a promising approach with remarkable potential for investigating the pathogenesis of GC and identifying novel therapeutic targets, as well as useful biomarkers. In this review, we will summarize the recent advances in the understanding of the molecular pathogenesis of GC, focusing on the potential use of these genetic and epigenetic alterations as diagnostic biomarkers and novel therapeutic targets.

Original languageEnglish
Pages (from-to)3927-3937
Number of pages11
JournalWorld Journal of Gastroenterology
Volume20
Issue number14
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Stomach Neoplasms
Epigenomics
Genes
Chromatin Assembly and Disassembly
Therapeutics
Histone Code
Biomarkers
Exome
Vascular Endothelial Growth Factor Receptor-2
Untranslated RNA
Mutation
Second Primary Neoplasms
Nucleosomes
Neoplasm Genes
Gene Expression Profiling
DNA Methylation
Cadherins
MicroRNAs
Cell Adhesion
Neoplasms

Keywords

  • Epigenetic field defect
  • Gastric washes
  • Insulin-like growth factor 1 receptor
  • MicroRNA
  • Microsatellite instability
  • Next-generation sequencing

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

An updated review of gastric cancer in the next-generation sequencing era : Insights from bench to bedside and vice versa. / Yamamoto, Hiroyuki; Watanabe, Yoshiyuki; Maehata, Tadateru; Morita, Ryo; Yoshida, Yoshihito; Oikawa, Ritsuko; Ishigooka, Shinya; Ozawa, Shun Ichiro; Matsuo, Yasumasa; Hosoya, Kosuke; Yamashita, Masaki; Taniguchi, Hiroaki; Nosho, Katsuhiko; Suzuki, Hiromu; Yasuda, Hiroshi; Shinomura, Yasuhisa; Itoh, Fumio.

In: World Journal of Gastroenterology, Vol. 20, No. 14, 2014, p. 3927-3937.

Research output: Contribution to journalArticle

Yamamoto, H, Watanabe, Y, Maehata, T, Morita, R, Yoshida, Y, Oikawa, R, Ishigooka, S, Ozawa, SI, Matsuo, Y, Hosoya, K, Yamashita, M, Taniguchi, H, Nosho, K, Suzuki, H, Yasuda, H, Shinomura, Y & Itoh, F 2014, 'An updated review of gastric cancer in the next-generation sequencing era: Insights from bench to bedside and vice versa', World Journal of Gastroenterology, vol. 20, no. 14, pp. 3927-3937. https://doi.org/10.3748/wjg.v20.i14.3927
Yamamoto, Hiroyuki ; Watanabe, Yoshiyuki ; Maehata, Tadateru ; Morita, Ryo ; Yoshida, Yoshihito ; Oikawa, Ritsuko ; Ishigooka, Shinya ; Ozawa, Shun Ichiro ; Matsuo, Yasumasa ; Hosoya, Kosuke ; Yamashita, Masaki ; Taniguchi, Hiroaki ; Nosho, Katsuhiko ; Suzuki, Hiromu ; Yasuda, Hiroshi ; Shinomura, Yasuhisa ; Itoh, Fumio. / An updated review of gastric cancer in the next-generation sequencing era : Insights from bench to bedside and vice versa. In: World Journal of Gastroenterology. 2014 ; Vol. 20, No. 14. pp. 3927-3937.
@article{f006d61543694a80ac6b40fed990c144,
title = "An updated review of gastric cancer in the next-generation sequencing era: Insights from bench to bedside and vice versa",
abstract = "Gastric cancer (GC) is one of the most common malignancies and remains the second leading cause of cancer-related death worldwide. There is an increasing understanding of the roles that genetic and epigenetic alterations play in GCs. Recent studies using nextgeneration sequencing (NGS) have revealed a number of potential cancer-driving genes in GC. Whole-exome sequencing of GC has identified recurrent somatic mutations in the chromatin remodeling gene ARID1A and alterations in the cell adhesion gene FAT4, a member of the cadherin gene family. Mutations in chromatin remodeling genes (ARID1A, MLL3 and MLL) have been found in 47{\%} of GCs. Whole-genome sequencing and whole-transcriptome sequencing analyses have also discovered novel alterations in GC. Recent studies of cancer epigenetics have revealed widespread alterations in genes involved in the epigenetic machinery, such as DNA methylation, histone modifications, nucleosome positioning, noncoding RNAs and microRNAs. Recent advances in molecular research on GC have resulted in the introduction of new diagnostic and therapeutic strategies into clinical settings. The antihuman epidermal growth receptor 2 (HER2) antibody trastuzumab has led to an era of personalized therapy in GC. In addition, ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor (VEGFR)-2, is the first biological treatment that showed survival benefits as a single-agent therapy in patients with advanced GC who progressed after firstline chemotherapy. Using NGS to systematically identify gene alterations in GC is a promising approach with remarkable potential for investigating the pathogenesis of GC and identifying novel therapeutic targets, as well as useful biomarkers. In this review, we will summarize the recent advances in the understanding of the molecular pathogenesis of GC, focusing on the potential use of these genetic and epigenetic alterations as diagnostic biomarkers and novel therapeutic targets.",
keywords = "Epigenetic field defect, Gastric washes, Insulin-like growth factor 1 receptor, MicroRNA, Microsatellite instability, Next-generation sequencing",
author = "Hiroyuki Yamamoto and Yoshiyuki Watanabe and Tadateru Maehata and Ryo Morita and Yoshihito Yoshida and Ritsuko Oikawa and Shinya Ishigooka and Ozawa, {Shun Ichiro} and Yasumasa Matsuo and Kosuke Hosoya and Masaki Yamashita and Hiroaki Taniguchi and Katsuhiko Nosho and Hiromu Suzuki and Hiroshi Yasuda and Yasuhisa Shinomura and Fumio Itoh",
year = "2014",
doi = "10.3748/wjg.v20.i14.3927",
language = "English",
volume = "20",
pages = "3927--3937",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "14",

}

TY - JOUR

T1 - An updated review of gastric cancer in the next-generation sequencing era

T2 - Insights from bench to bedside and vice versa

AU - Yamamoto, Hiroyuki

AU - Watanabe, Yoshiyuki

AU - Maehata, Tadateru

AU - Morita, Ryo

AU - Yoshida, Yoshihito

AU - Oikawa, Ritsuko

AU - Ishigooka, Shinya

AU - Ozawa, Shun Ichiro

AU - Matsuo, Yasumasa

AU - Hosoya, Kosuke

AU - Yamashita, Masaki

AU - Taniguchi, Hiroaki

AU - Nosho, Katsuhiko

AU - Suzuki, Hiromu

AU - Yasuda, Hiroshi

AU - Shinomura, Yasuhisa

AU - Itoh, Fumio

PY - 2014

Y1 - 2014

N2 - Gastric cancer (GC) is one of the most common malignancies and remains the second leading cause of cancer-related death worldwide. There is an increasing understanding of the roles that genetic and epigenetic alterations play in GCs. Recent studies using nextgeneration sequencing (NGS) have revealed a number of potential cancer-driving genes in GC. Whole-exome sequencing of GC has identified recurrent somatic mutations in the chromatin remodeling gene ARID1A and alterations in the cell adhesion gene FAT4, a member of the cadherin gene family. Mutations in chromatin remodeling genes (ARID1A, MLL3 and MLL) have been found in 47% of GCs. Whole-genome sequencing and whole-transcriptome sequencing analyses have also discovered novel alterations in GC. Recent studies of cancer epigenetics have revealed widespread alterations in genes involved in the epigenetic machinery, such as DNA methylation, histone modifications, nucleosome positioning, noncoding RNAs and microRNAs. Recent advances in molecular research on GC have resulted in the introduction of new diagnostic and therapeutic strategies into clinical settings. The antihuman epidermal growth receptor 2 (HER2) antibody trastuzumab has led to an era of personalized therapy in GC. In addition, ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor (VEGFR)-2, is the first biological treatment that showed survival benefits as a single-agent therapy in patients with advanced GC who progressed after firstline chemotherapy. Using NGS to systematically identify gene alterations in GC is a promising approach with remarkable potential for investigating the pathogenesis of GC and identifying novel therapeutic targets, as well as useful biomarkers. In this review, we will summarize the recent advances in the understanding of the molecular pathogenesis of GC, focusing on the potential use of these genetic and epigenetic alterations as diagnostic biomarkers and novel therapeutic targets.

AB - Gastric cancer (GC) is one of the most common malignancies and remains the second leading cause of cancer-related death worldwide. There is an increasing understanding of the roles that genetic and epigenetic alterations play in GCs. Recent studies using nextgeneration sequencing (NGS) have revealed a number of potential cancer-driving genes in GC. Whole-exome sequencing of GC has identified recurrent somatic mutations in the chromatin remodeling gene ARID1A and alterations in the cell adhesion gene FAT4, a member of the cadherin gene family. Mutations in chromatin remodeling genes (ARID1A, MLL3 and MLL) have been found in 47% of GCs. Whole-genome sequencing and whole-transcriptome sequencing analyses have also discovered novel alterations in GC. Recent studies of cancer epigenetics have revealed widespread alterations in genes involved in the epigenetic machinery, such as DNA methylation, histone modifications, nucleosome positioning, noncoding RNAs and microRNAs. Recent advances in molecular research on GC have resulted in the introduction of new diagnostic and therapeutic strategies into clinical settings. The antihuman epidermal growth receptor 2 (HER2) antibody trastuzumab has led to an era of personalized therapy in GC. In addition, ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor (VEGFR)-2, is the first biological treatment that showed survival benefits as a single-agent therapy in patients with advanced GC who progressed after firstline chemotherapy. Using NGS to systematically identify gene alterations in GC is a promising approach with remarkable potential for investigating the pathogenesis of GC and identifying novel therapeutic targets, as well as useful biomarkers. In this review, we will summarize the recent advances in the understanding of the molecular pathogenesis of GC, focusing on the potential use of these genetic and epigenetic alterations as diagnostic biomarkers and novel therapeutic targets.

KW - Epigenetic field defect

KW - Gastric washes

KW - Insulin-like growth factor 1 receptor

KW - MicroRNA

KW - Microsatellite instability

KW - Next-generation sequencing

UR - http://www.scopus.com/inward/record.url?scp=84898413155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898413155&partnerID=8YFLogxK

U2 - 10.3748/wjg.v20.i14.3927

DO - 10.3748/wjg.v20.i14.3927

M3 - Article

C2 - 24744582

AN - SCOPUS:84898413155

VL - 20

SP - 3927

EP - 3937

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 14

ER -